Medolife Rx – Trademark Portfolio

Entity Type: 03

Medolife Rx holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 3 (Cosmetics & Cleaning) — 2 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include AELIA. The owner is based in Beverly Hills, CA.

433 N. Camden Drive

Beverly Hills, CA 90210

4 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

AELIA
AELIA
Registered 2021
AELIA
AELIA
Registered 2021
QUANTRX
QUANTRX
Abandoned 2021
QUANTRX
QUANTRX
Abandoned 2021

Trademark Classifications

Medolife Rx's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

3
Cosmetics & Cleaning (2 filings)

Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring

5
Pharmaceuticals (2 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Medolife Rx have?

Medolife Rx has 4 U.S. trademarks filed with the USPTO. Of these, 2 registered, 2 abandoned.

What trademark classes does Medolife Rx file in?

Medolife Rx files trademarks across 2 Nice Classification classes. The most active classes are Class 3 (Cosmetics & Cleaning), Class 5 (Pharmaceuticals). Class 3 covers bleaching preparations and other substances for laundry use; cleaning, polishing, scouring.

What are Medolife Rx's most well-known trademarks?

Medolife Rx's registered trademark portfolio includes well-known marks such as AELIA. These are among 2 currently registered trademarks in the portfolio.

What is Medolife Rx's trademark registration success rate?

Medolife Rx has a 50% trademark registration rate, with 2 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.